Login to Your Account

Innate's stock tanks as lirilumab flunks Opdivo combo trial

By Cormac Sheridan
Staff Writer

Monday, November 27, 2017

DUBLIN – Shares in Innate Pharma SA slumped by 40 percent Thursday on news that a combination of its first-in-class antibody, lirilumab, which targets three inhibitory killer-cell immunoglobulin-like receptors, and the PD-1 inhibitor Opdivo failed to demonstrate efficacy in patients with SCCHN.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription